Novel Agent MK-6482 Shows Promise in Renal Cell Carcinoma

Published: Sunday, Feb 16, 2020
Toni K. Choueiri, MD, UT Southwestern Medical Center

Toni K. Choueiri, MD
The oral hypoxia-inducible factor (HIF)-2α inhibitor MK-6482 induced a partial response rate of 24% and a disease control rate of 80% in patients with advanced clear cell renal cell carcinoma (ccRCC), according to findings from a phase I/II study presented at the 2020 Genitourinary Cancers Symposium.1

Overall, 13 of 55 patients had partial responses, and responses occurred regardless of disease risk status. The duration of response had yet to be reached, but the vast majority of responses persisted to 6 weeks and beyond.

“After a median follow-up of 13 months, we observed promising clinical activity in patients with heavily pretreated advanced clear cell renal cell carcinoma,” said Toni Choueiri, MD, PhD, of Dana-Farber Cancer Institute. “A majority of the patients had received 3 or more prior lines of therapy. A phase III trial of MK-6482 is ongoing in patients with previously treated advanced clear cell renal cell carcinoma.”
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication